Last reviewed · How we verify

Metocurine (dimethyltubocurarinium)

Eli Lilly · FDA-approved active Quality 26/100

At a glance

Generic namedimethyltubocurarinium
SponsorEli Lilly
Drug classmetocurine
TargetAcetylcholine receptor
Therapeutic areaNeuroscience
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: